Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway

Loukik Arora; Chakrabhavi Dhananjaya Mohan; Min Hee Yang; Shobith Rangappa; Amudha Deivasigamani; Alan Prem Kumar; Ajaikumar B. Kunnumakkara; Manoj Garg; Arunachalam Chinnathambi; Sulaiman Ali Alharbi; Tahani Awad Alahmadi; Kanchugarakoppal S. Rangappa; Kam Man Hui; Gautam Sethi; Kwang Seok Ahn

doi:10.3390/cancers13215479

Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway

Loukik Arora
, Chakrabhavi Dhananjaya Mohan
, Min Hee Yang
, Shobith Rangappa
, Amudha Deivasigamani
, Alan Prem Kumar
, Ajaikumar B. Kunnumakkara
, Manoj Garg
, Arunachalam Chinnathambi
, Sulaiman Ali Alharbi
, Tahani Awad Alahmadi
, Kanchugarakoppal S. Rangappa
, Kam Man Hui
, Gautam Sethi
, Kwang Seok Ahn

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

STAT3 is an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression. Persistent activation of STAT3 is observed in human.

Original language	English
Article number	5479
Journal	Cancers
Volume	13
Issue number	21
DOIs	https://doi.org/10.3390/cancers13215479
Publication status	Published - 1 Nov 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Orthotopic
SHP2
STAT3 signaling inhibitor
Tris DBA
Xenograft

Access to Document

10.3390/cancers13215479

Cite this

Arora, L., Mohan, C. D., Yang, M. H., Rangappa, S., Deivasigamani, A., Kumar, A. P., Kunnumakkara, A. B., Garg, M., Chinnathambi, A., Alharbi, S. A., Alahmadi, T. A., Rangappa, K. S., Hui, K. M., Sethi, G., & Ahn, K. S. (2021). Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway. Cancers, 13(21), Article 5479. https://doi.org/10.3390/cancers13215479

@article{68dcc77cb9554077a0b44792b27e603f,

title = "Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway",

abstract = "STAT3 is an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression. Persistent activation of STAT3 is observed in human.",

keywords = "Orthotopic, SHP2, STAT3 signaling inhibitor, Tris DBA, Xenograft",

author = "Loukik Arora and Mohan, \{Chakrabhavi Dhananjaya\} and Yang, \{Min Hee\} and Shobith Rangappa and Amudha Deivasigamani and Kumar, \{Alan Prem\} and Kunnumakkara, \{Ajaikumar B.\} and Manoj Garg and Arunachalam Chinnathambi and Alharbi, \{Sulaiman Ali\} and Alahmadi, \{Tahani Awad\} and Rangappa, \{Kanchugarakoppal S.\} and Hui, \{Kam Man\} and Gautam Sethi and Ahn, \{Kwang Seok\}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = nov,

day = "1",

doi = "10.3390/cancers13215479",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "21",

}

Arora, L, Mohan, CD, Yang, MH, Rangappa, S, Deivasigamani, A, Kumar, AP, Kunnumakkara, AB, Garg, M, Chinnathambi, A, Alharbi, SA, Alahmadi, TA, Rangappa, KS, Hui, KM, Sethi, G & Ahn, KS 2021, 'Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway', Cancers, vol. 13, no. 21, 5479. https://doi.org/10.3390/cancers13215479

Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway. / Arora, Loukik; Mohan, Chakrabhavi Dhananjaya; Yang, Min Hee et al.
In: Cancers, Vol. 13, No. 21, 5479, 01.11.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway

AU - Arora, Loukik

AU - Mohan, Chakrabhavi Dhananjaya

AU - Yang, Min Hee

AU - Rangappa, Shobith

AU - Deivasigamani, Amudha

AU - Kumar, Alan Prem

AU - Kunnumakkara, Ajaikumar B.

AU - Garg, Manoj

AU - Chinnathambi, Arunachalam

AU - Alharbi, Sulaiman Ali

AU - Alahmadi, Tahani Awad

AU - Rangappa, Kanchugarakoppal S.

AU - Hui, Kam Man

AU - Sethi, Gautam

AU - Ahn, Kwang Seok

PY - 2021/11/1

Y1 - 2021/11/1

N2 - STAT3 is an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression. Persistent activation of STAT3 is observed in human.

AB - STAT3 is an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression. Persistent activation of STAT3 is observed in human.

KW - Orthotopic

KW - SHP2

KW - STAT3 signaling inhibitor

KW - Tris DBA

KW - Xenograft

UR - https://www.scopus.com/pages/publications/85118196743

U2 - 10.3390/cancers13215479

DO - 10.3390/cancers13215479

M3 - Article

AN - SCOPUS:85118196743

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 21

M1 - 5479

ER -

Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this